Related references
Note: Only part of the references are listed.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
C. F. Deacon et al.
DIABETES OBESITY & METABOLISM (2016)
Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors
Eita Sasaki et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2016)
Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
Dong-Sung Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Dipeptidyl Peptidase-4 Greatly Contributes to the Hydrolysis of Vildagliptin in Human Liver
Mitsutoshi Asakura et al.
DRUG METABOLISM AND DISPOSITION (2015)
Idiosyncratic Liver Injury Induced by Vildagliptin With Successful Switch to Linagliptin in a Hemodialyzed Diabetic Patient
Noriaki Kurita et al.
DIABETES CARE (2014)
Human Nitrilase-like Protein Does Not Catalyze the Hydrolysis of Vildagliptin
Mitsutoshi Asakura et al.
DRUG METABOLISM AND PHARMACOKINETICS (2014)
A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse
Anna Moles et al.
JOURNAL OF HEPATOLOGY (2014)
Development of a cell-based assay system considering drug metabolism and immune-and inflammatory-related factors for the risk assessment of drug-induced liver injury
Azusa Yano et al.
TOXICOLOGY LETTERS (2014)
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Thomas Karagiannis et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved
Laia Tolosa et al.
ARCHIVES OF TOXICOLOGY (2013)
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
Mika Nabeno et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man
S. J. Busch et al.
DIABETES OBESITY & METABOLISM (2013)
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model
B. A. Omar et al.
DIABETOLOGIA (2013)
Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity
P. A. Spagnuolo et al.
LEUKEMIA (2013)
Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
Yan-Ling He
CLINICAL PHARMACOKINETICS (2012)
Stimulation of Human Monocytic THP-1 Cells by Metabolic Activation of Hepatotoxic Drugs
Shinya Endo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Metabolic Activation and Inflammation Reactions Involved in Carbamazepine-Induced Liver Injury
Satonori Higuchi et al.
TOXICOLOGICAL SCIENCES (2012)
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
Aiying Wang et al.
BMC Pharmacology & Toxicology (2012)
Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway
Katsuhiko Mizuno et al.
ARCHIVES OF TOXICOLOGY (2011)
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
Gary A. Herman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2011)
Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes
Lei Guo et al.
DRUG METABOLISM AND DISPOSITION (2011)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
S100 Calgranulins in inflammatory arthritis
Chandima Perera et al.
IMMUNOLOGY AND CELL BIOLOGY (2010)
Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway
Katsuhiko Mizuno et al.
LIFE SCIENCES (2010)
Mechanisms of Immune-Mediated Liver Injury
David H. Adams et al.
TOXICOLOGICAL SCIENCES (2010)
Expression and Role of Myeloid-related Protein-14 in Clinical and Experimental Sepsis
Marieke A. D. van Zoelen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Covalent Modifiers: An Orthogonal Approach to Drug Design
Michele H. Potashman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
Yan-Ling He et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Differential gene expression patterns coupled to commitment and acquisition of phenotypic hallmarks during neutrophil differentiation of human leukaemia HL-60 cells
Faustino Mollinedo et al.
GENE (2008)
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
Y.-L. He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules
Dirk Foell et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Mechanisms of drug-induced liver injury
MP Holt et al.
AAPS JOURNAL (2006)
Calprotectin expression in human monocytes:: Induction by Porphyromonas gingivalis lipopolysaccharide, tumor necrosis factor-α, and Interleukin-1β
Suryono et al.
JOURNAL OF PERIODONTOLOGY (2005)
Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils
C Ryckman et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Proinflammatory S100 proteins in arthritis and autoimmune disease
D Foell et al.
ARTHRITIS AND RHEUMATISM (2004)
Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties
S Wilkening et al.
DRUG METABOLISM AND DISPOSITION (2003)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Phagocyte-specific S100 proteins:: a novel group of proinflammatory molecules
J Roth et al.
TRENDS IN IMMUNOLOGY (2003)
Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysaccharide via the CD-14-toll-like receptor-nuclear factor kappa B pathway
J Kido et al.
JOURNAL OF PERIODONTAL RESEARCH (2003)
Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxic to HepG2 cells
Y Yamamoto et al.
DRUG METABOLISM AND DISPOSITION (2002)
Share Paper
